Northwestern Cancer Prevention Consortium

西北癌症预防联盟

• 批准号: 10006889
• 负责人: SEEMA Ahsan KHAN
• 金额: $ 197.5万
• 依托单位: NORTHWESTERN UNIVERSITY AT CHICAGO
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-03 至 2024-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10006889
• 关键词: Advisory Committees; Area; Biological; Biological Markers; Breast; Cancer Center Support Grant; Cancer Prevention Trial; Cancer Science; Cities; Clinic; Clinical; Clinical Research; Clinical Trials; Collaborations; Colon; Colon Carcinoma; Communication; Comprehensive Cancer Center; Conduct Clinical Trials; Consultations; Development; Disease; Dose; Drug Delivery Systems; Ensure; Evaluation; Fostering; Fright; Fruit; Genetic Predisposition to Disease; Goals; Incidence; Individual; Institution; Intervention; Investigation; Knowledge; Lead; Leadership; Lesion; Liver; Lung; Malignant Neoplasms; Malignant neoplasm of liver; Malignant neoplasm of lung; Malignant neoplasm of pancreas; Mentors; Methods; Monitor; Mutation; Organ; Pancreas; Pathology; Pathway interactions; Patients; Pharmaceutical Preparations; Physicians; Population; Prevention; Prevention Research; Process; Reproducibility; Research; Research Infrastructure; Research Personnel; Resources; Science; Scientist; Site; Sum; Technology; Testing; Toxic effect; Transdermal substance administration; Universities; Ursidae Family; Work; base; biomarker selection; cancer chemoprevention; cancer prevention; cancer therapy; cancer type; design; early phase clinical trial; early phase trial; improved; innovation; malignant breast neoplasm; malignant oropharynx neoplasm; member; nanoarchitecture; novel; novel marker; predictive marker; programs; protocol development; recruit; reduce symptoms; success; targeted agent; trial design

Northwestern University proposes to continue to lead a consortium of organizations, the Northwestern Cancer Prevention Consortium (NCPC), to design and conduct early phase clinical trials aimed at developing new options for the prevention of cancer. To date, NCPC trials, 19 in total, have accrued 534 patients (354 from the 2003 consortium and 175 from the 2012 consortium), targeting multiple organ sites and a variety of agents. We have tested innovative concepts, e.g., transdermal drug delivery, and utilized novel biomarkers, such as nanocytological alterations. Our proposal to renew the NCPC, under the leadership of Seema A. Khan MD includes academic partners included in the current consortium and new members who are expected to add important strengths to it (the University of Toronto and City of Hope). In the new cycle of the NCPC, we will continue to build on promising approaches based on prior or ongoing successful trials, while providing oversight, consultation, and administrative support to cancer prevention research teams. We will assist in the design of cancer prevention trials, in proposal and protocol development, and in the implementation of such trials. Our overarching goal is to continue our contributions to cancer prevention science through the development of innovative, transformative, early phase trials testing new conceptual approaches that will enable clinical advances in the prevention of cancer. Our Aims are to 1. Advance high priorities in cancer prevention, for maximum impact on cancer incidence when these are advanced into clinical use. These priorities include (i) investigate novel agents and repurposed agents that target mutations and pathways known to be important in the development of cancer, (ii) novel or established biomarkers to identify individuals most like to predict benefit from a given approach, (iii) trials that will result in unifying biological themes across different organ sites, leading to protection against more than one cancer type, (iv) test innovative dosing and delivery methods, to reduce the symptom and toxicity burden for users of cancer prevention agents. 2. Provide consultation, scientific guidance, and mentoring to consortium investigators who are proposing new trial concepts; assist consortium investigators through trial design, initiation, conduct, and analysis; and to serve as the administrative hub of the consortium. We will foster communication, collaboration, and sharing of available resources between consortium members and across consortia, to maximize impact of clinical trials testing similar interventions or in similar populations. Serve as a liaison between the consortium and the NCI DCP, by maintaining and improving an NCPC 3. Advance the science of cancer prevention, through evaluation and selection of innovative or transformative concepts that result in progress that is greater than the sum of knowledge gained from the specific goals of an individual trial. We will be guided in this process by an Advisory Committee with a diverse background in cancer prevention research.

西北大学建议继续领导一个组织联盟，西北癌症 预防联盟（NCPC），设计和进行早期临床试验，旨在开发新的 预防癌症的选择。迄今为止，NCPC试验，总共19个，已经累积了534名患者（354名来自 2003年联盟和175从2012年联盟），针对多个器官网站和各种代理。我们 已经测试了创新的概念，例如，经皮给药，并利用新的生物标志物，如 纳米细胞学改变我们提议在Seema A. Khan MD 包括目前联盟中的学术合作伙伴和预计将增加的新成员。 它的重要优势（多伦多大学和希望之城）。在新一轮的NCPC中， 继续以基于先前或正在进行的成功试验的有希望的方法为基础， 对癌症预防研究团队的监督、咨询和行政支持。我们将协助合适 癌症预防试验的设计，在建议和协议的制定，并在实施这样的 审判我们的首要目标是继续为癌症预防科学做出贡献 通过开发创新的、变革性的、早期阶段的试验， 这些方法将使癌症预防的临床进展成为可能。我们的目标是1。 推进癌症预防的高度优先事项，以最大限度地降低癌症发病率， 进入临床使用。这些优先事项包括（i）研究新的代理人和重新用途的代理人， 已知在癌症发展中重要的靶向突变和途径，（ii）新的或 已建立的生物标志物，以确定最有可能预测从给定方法中获益的个体，（iii）试验 这将导致统一不同器官部位的生物学主题，从而防止更多的 （iv）测试创新的给药和递送方法，以减轻症状， 癌症预防剂使用者的毒性负担。2.提供咨询、科学指导， 指导提出新试验概念的联合研究者;协助联合研究者 通过试验设计、启动、实施和分析;并作为 财团我们将促进沟通、协作和共享可用资源 在联盟成员之间和联盟之间，最大限度地发挥临床试验的影响， 干预或类似人群。作为联合体和NCI DCP之间的联络人， 保持和改进NCPC 3。通过评估推进癌症预防科学 并选择创新或变革性概念，从而取得的进展大于 从个体试验的特定目标中获得的知识。我们将在这一过程中得到指导 由一个在癌症预防研究方面具有不同背景的咨询委员会进行。